Skip to main content
. 2020 Dec 10;8(2):e001315. doi: 10.1136/jitc-2020-001315

Figure 5.

Figure 5

Patients with EPHA mutation showed a favorable clinical benefit in lung adenocarcinoma (LUAD) when treated with immune checkpoint inhibitors. (A–F) Kaplan-Meier survival curves comparing progression-free survival (PFS) or overall survival (OS) between the EPHA mutation group and EPHA wide-type group in China cohort and two validation cohorts.